Aspire Biopharma Board sets share limit for 2024 Stock Incentive Plan at 4,890,000 shares

Aspire Biopharma Holdings, Inc.

Board confirmed share limit of 4,890,000 shares for the 2024 Stock Incentive Plan, which was approved by stockholders in Feb 2025.
Approved forms of Restricted Stock Unit and Stock Option award agreements under the Plan.
Plan allows grants of equity awards to employees, directors, and consultants to align with long-term stockholder interests.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.